Evidence-based peptide information for research and educational purposes only.
Navaro HealthNavaro Health
GH Secretagogues

HGH 191AA (Somatropin)

← Back to Library
Label-verified GH Axis Repair
Educational reference only. Read the full disclaimer. The protocols below are not automatically an FDA-approved or clinically verified regimen unless explicitly marked as label-verified or human-trial protocol above.

Compound Profile

HGH 191AA (Somatropin) is reviewed here for growth-hormone signaling and recovery context.

Research Summary

Evidence Strength Strong
Primary Evidence

Approved label, human clinical studies, regulatory sources

Research Focus

Growth-hormone signaling, Recovery, Body composition

Mechanism

Well characterized for approved products: GHR

Long-Term Data

Available for approved or studied uses.

Current Consensus

Research support is strongest when tied to approved products and studied use cases.

Route(s) Subcutaneous
Typical dose 1 IU
Dosing window Morning Fasted / Pre-Bed
Receptor / target GHR
Properties Not listed
Pre-mixed No

How HGH 191AA (Somatropin) works in the body

Growth hormone (somatropin) acts across the body, largely through IGF-1.

Muscle (Approved (GH deficiency))

Promotes muscle protein synthesis and lean mass. Approved for growth-hormone deficiency; other uses are off-label.

Bone (Approved (GH deficiency))

Supports bone turnover and density; central to its approved use in growth and bone-related indications.

Educational only, not medical advice. Labels describe the type of research behind each area, not a recommendation.

Protocols

Standard Protocol

TimeframeDoseNotes
Weeks 1-41 IU dailyAdministered once daily (before bedtime). Conservative start for anti-aging protocol.
Weeks 5-82 IU dailyAdministered once daily (before bedtime). Standard body composition dose.
Weeks 9-163 IU dailyAdministered once daily (before bedtime). Upper anti-aging dose.
Weeks 17+4 IU dailyAdministered once daily (before bedtime). Performance protocol ceiling.

Protocol example for research-context comparison; verify against the evidence status and listed medical sources.

Alternative: Gradual Approach

TimeframeDoseNotes
Weeks 1-80.5 IU dailyUltra-conservative start for women or older adults (>60); assess glucose tolerance.
Weeks 9-161 IU dailyAdvance only if fasting glucose unchanged from baseline.

Alternative research-context example; not an approved-label regimen unless marked above.

Protocol logic check

Protocol context: GH-axis protocols are not 'more is better.' The logic is pulse quality, recovery time, IGF-1/glucose monitoring, and avoiding receptor desensitization, edema, appetite spikes, numbness, or blood-pressure strain. Entry context: target (GHR); route Subcutaneous; timing Morning Fasted / Pre-Bed. Label/trial anchors carry more weight than forum-style escalation. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. GH-axis stacking should be filtered for total IGF-1/glucose burden, not just expected synergy.

Medical literature and study context

Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.

Evidence positionApproved drug-label evidence exists for at least one product/indication, so label dosing, contraindications, and warnings are the strongest anchors.
Where studiedStudied around pituitary GH signaling, IGF-1 response, body-composition endpoints, growth-hormone deficiency models, or discontinued anabolic programs depending on the compound.
Source systems checkedDailyMed/NLM labels; FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records
Target and route contextTarget/receptor: GHR. Route(s): Subcutaneous. Dosing window on page: Morning Fasted / Pre-Bed.
Protocol anchorApproved-label anchor: Somatropin dosing is product-, indication-, age-, and weight-specific. Norditropin examples include pediatric GHD 0.17-0.24 mg/kg/week divided 6-7 days weekly and adult GHD starting around 0.2 mg/day or 0.004 mg/kg/day with titration.
Main evidence limitKey limitation: label evidence applies to labeled products, doses, routes, and populations; off-label or compounded versions may not share that evidence.

Source-linked findings

  • Somatropin products have approved labels for defined growth-hormone deficiency and selected pediatric/adult indications; that label evidence should not be generalized to enhancement use.
  • IGF-1, glucose, edema, sleep apnea, intracranial hypertension symptoms, malignancy history, and scoliosis/progression risk are key monitoring themes.
  • No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.

Protocol and study notes

  • Approved-label anchor: Somatropin dosing is product-, indication-, age-, and weight-specific. Norditropin examples include pediatric GHD 0.17-0.24 mg/kg/week divided 6-7 days weekly and adult GHD starting around 0.2 mg/day or 0.004 mg/kg/day with titration.
  • On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-4, 1 IU daily; Alternative: Gradual Approach: Weeks 1-8, 0.5 IU daily.
  • Key limitation: label evidence applies to labeled products, doses, routes, and populations; off-label or compounded versions may not share that evidence.
  • Monitor IGF-1 response, fasting glucose/A1c, edema, carpal-tunnel symptoms, blood pressure, sleep apnea, and malignancy history.

Selected medical sources

Independent evidence

Approved label dosing: Somatropin dosing is product-, indication-, age-, and weight-specific. Norditropin examples include pediatric GHD 0.17-0.24 mg/kg/week divided 6-7 days weekly and adult GHD starting around 0.2 mg/day or 0.004 mg/kg/day with titration.
Independent safety notes: No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.

Regulatory status: approved drug label available for somatropin products

Storage

Norditropin and Genotropin products are generally refrigerated 2-8 C before use; in-use limits vary by product/strength. Genotropin reconstituted cartridges are refrigerated and discarded after 28 days.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.

  • Active cancer or evidence of neoplastic activity: exogenous GH and IGF-1 directly accelerates tumor cell proliferation; GH should not be initiated or continued if active malignancy is detected.
  • Intracranial lesions that are not fully inactive and treated: antitumor therapy must be complete prior to GH initiation.
  • Insulin resistance or pre-existing type 2 diabetes: HGH is diabetogenic at therapeutic doses; progressively worsens insulin sensitivity; fasting glucose must be monitored throughout.
  • Diabetic ketoacidosis.
  • Proliferative or severe non-proliferative diabetic retinopathy: GH/IGF-1 elevation worsens retinal vasculopathy.
  • Concurrent use with CJC-1295 No DAC, CJC-1295 DAC, ipamorelin, tesamorelin, GHRP-2, GHRP-6, or sermorelin: redundant and counterproductive GH axis stimulation; secretagogues stimulate a pituitary that exogenous HGH has already suppressed.
  • Acute critical illness: increased mortality observed in critically ill patients (open heart surgery, abdominal surgery, multiple trauma, acute respiratory failure) receiving high-dose GH; do not use in ICU or perioperative settings.
  • Pregnancy: limited human data; use only if clearly needed; associated with fetal risks in animal studies.
  • Breastfeeding: not known whether excreted in human milk; caution advised.
  • Known hypersensitivity to somatropin or excipients (including benzyl alcohol in some formulations: absolute contraindication in newborns).
  • Active acromegaly: exogenous GH in already-excess GH state.
  • Closed epiphyses in pediatric patients being treated for growth failure: dose adjustment required.
  • Concomitant high-dose glucocorticoid therapy: inhibits IGF-1 production and growth-promoting effects; glucocorticoid replacement doses should be carefully adjusted.
  • Concomitant CYP450-metabolized drugs: GH increases CYP450 clearance; adjust cyclosporine, sex steroids, anticonvulsants as needed.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.

  • Water retention and peripheral edema: the most commonly reported early adverse effect; GH-mediated sodium and fluid retention; typically most pronounced in the first 4-8 weeks; responsive to dose reduction.
  • Arthralgia (joint pain): GH-mediated periarticular fluid accumulation; particularly wrists, knees, and ankles.
  • Myalgia (muscle pain): GH-related; typically transient.
  • Carpal tunnel syndrome: GH-mediated median nerve compression from fluid retention; more common in adults; may require dose reduction or discontinuation.
  • Paresthesia (tingling/numbness): in hands and feet; from GH-related fluid pressure on peripheral nerves.
  • Decreased insulin sensitivity: progressive with dose and duration; the primary metabolic adverse effect of sustained exogenous GH; monitor fasting glucose.
  • Elevated fasting blood glucose: direct consequence of GH-induced insulin resistance.
  • Peripheral swelling (hands, feet, face): edema, particularly in the first weeks.
  • Headache: vasodilation and fluid shifts.
  • Benign intracranial hypertension: rare; typically in pediatric patients; presents as headache, visual changes, nausea; resolves with dose reduction.
  • Lipoatrophy at injection sites: with prolonged injection at the same site; rotate injection sites to prevent.
  • Pituitary suppression of endogenous GH: exogenous GH suppresses the HPG axis; gradual taper required upon cycle cessation to allow pituitary recovery.
  • Hypothyroidism: GH may reduce T4 to T3 conversion; monitor thyroid function with extended cycles.
  • Antibody formation: in rare subjects; typically low binding capacity and not clinically significant.
  • Gynecomastia: rare; associated with GH-induced IGF-1 elevation and secondary prolactin effects.
  • Diabetes mellitus: with sustained supraphysiologic doses in predisposed subjects.
  • Leukemia risk: reported in small number of pediatric patients; relationship to GH therapy uncertain; caution in subjects with prior malignancy.
  • Injection site reactions: pain, redness, swelling at subcutaneous sites; short-term and localized.

Compatibility

The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

IGF-1 LR3MGF (Mechano Growth Factor)

Reported contraindicated combinations:

CJC-1295 (No DAC / Modified GRF 1-29)CJC-1295 DACIpamorelinTesamorelinGHRP-2GHRP-6Sermorelin

Sources